Overview

Safety and Tolerability of Z-100 in Patients With Early HIV Infection

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to see if Z-100 (an investigational drug) treatment is safe in HIV patients who have never received treatment for their HIV, who have not been taking highly active antiretroviral therapy (HAART) for at least 8 weeks, or who have been stable on their current first or second HAART regimen for at least 12 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Zeria Pharmaceutical
Treatments:
Specific substance maruyama